Paper42921187PubMed
Exploiting key metabolic pathways of Mycobacterium tuberculosis for next-generation anti-tubercular drug discovery.
Thansila Parvin N and 2 others. Biochem Biophys Rep, 2026.
Cite this record
ConductScience Library. Exploiting key metabolic pathways of Mycobacterium tuberculosis for next-generation anti-tubercular drug discovery. Papers, record 42921187. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42921187
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Exploiting key metabolic pathways of Mycobacterium tuberculosis for next-generation anti-tubercular drug discovery.
- Journal
- Biochem Biophys Rep
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-10-26
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References186
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12368440 | The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. | Microbiology (Reading) | 2002 | https://conductscience.org/library/papers/12368440 | PubMed |
| 2 | 24429106 | Identification of shikimate kinase inhibitors among anti-Mycobacterium tuberculosis compounds by LC-MS. | Tuberculosis (Edinb) | 2014 | https://conductscience.org/library/papers/24429106 | PubMed |
| 3 | 36072222 | Understanding the contribution of metabolism to Mycobacterium tuberculosis drug tolerance. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/36072222 | PubMed |
| 4 | 30348661 | Promising New Antifungal Treatment Targeting Chorismate Synthase from Paracoccidioides brasiliensis. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/30348661 | PubMed |
| 5 | 18260104 | Structural studies of shikimate 5-dehydrogenase from Mycobacterium tuberculosis. | Proteins | 2008 | https://conductscience.org/library/papers/18260104 | PubMed |
| 6 | 16663714 | Glyphosate Inhibition of 5-Enolpyruvylshikimate 3-Phosphate Synthase from Suspension-Cultured Cells of Nicotiana silvestris. | Plant Physiol | 1984 | https://conductscience.org/library/papers/16663714 | PubMed |
| 7 | 22475559 | Synthesis and characterization of pyruvate-isoniazid analogs and their copper complexes as potential ICL inhibitors. | Bioorg Med Chem Lett | 2012 | https://conductscience.org/library/papers/22475559 | PubMed |
| 8 | 29654976 | Mechanism of irreversible inhibition of Mycobacterium tuberculosis shikimate kinase by ilimaquinone. | Biochim Biophys Acta Proteins Proteom | 2018 | https://conductscience.org/library/papers/29654976 | PubMed |
| 9 | 32306850 | Structure-based discovery of phenyl-diketo acids derivatives as Mycobacterium tuberculosis malate synthase inhibitors. | J Biomol Struct Dyn | 2021 | https://conductscience.org/library/papers/32306850 | PubMed |
| 10 | 18048912 | Role of the methylcitrate cycle in propionate metabolism and detoxification in Mycobacterium smegmatis. | Microbiology (Reading) | 2007 | https://conductscience.org/library/papers/18048912 | PubMed |
| 11 | 38339997 | Clinical considerations and pharmacokinetic interactions between HIV and tuberculosis therapeutics. | Expert Rev Clin Pharmacol | 2024 | https://conductscience.org/library/papers/38339997 | PubMed |
| 12 | 33791235 | Tuberculosis Drug Discovery: A Decade of Hit Assessment for Defined Targets. | Front Cell Infect Microbiol | 2021 | https://conductscience.org/library/papers/33791235 | PubMed |
| 13 | 27498028 | Protein kinase C-δ inhibitor, Rottlerin inhibits growth and survival of mycobacteria exclusively through Shikimate kinase. | Biochem Biophys Res Commun | 2016 | https://conductscience.org/library/papers/27498028 | PubMed |
| 14 | 33144641 | Demystifying the catalytic pathway of Mycobacterium tuberculosis isocitrate lyase. | Sci Rep | 2020 | https://conductscience.org/library/papers/33144641 | PubMed |
| 15 | 21093117 | Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection. | Eur J Med Chem | 2011 | https://conductscience.org/library/papers/21093117 | PubMed |
| 16 | 15606760 | Involvement of two positively charged residues of Chlamydomonas reinhardtii glyceraldehyde-3-phosphate dehydrogenase in the assembly process of a bi-enzyme complex involved in CO2 assimilation. | Eur J Biochem | 2004 | https://conductscience.org/library/papers/15606760 | PubMed |
| 17 | 33688722 | Covalent Inactivation of Mycobacterium tuberculosis Isocitrate Lyase by cis-2,3-Epoxy-Succinic Acid. | ACS Chem Biol | 2021 | https://conductscience.org/library/papers/33688722 | PubMed |
| 18 | 28265055 | Glyoxylate detoxification is an essential function of malate synthase required for carbon assimilation in Mycobacterium tuberculosis. | Proc Natl Acad Sci U S A | 2017 | https://conductscience.org/library/papers/28265055 | PubMed |
| 19 | 22189133 | Cu-mediated N-arylation of 1,2,3-triazin-4-ones: synthesis of fused triazinone derivatives as potential inhibitors of chorismate mutase. | Bioorg Med Chem Lett | 2012 | https://conductscience.org/library/papers/22189133 | PubMed |
| 20 | 36197914 | Role of Half-of-Sites Reactivity and Inter-Subunit Communications in DAHP Synthase Catalysis and Regulation. | Biochemistry | 2022 | https://conductscience.org/library/papers/36197914 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42921187
GET https://conductscience.org/api/papers/v1/42921187/references?page=2